Telix Pharmaceuticals has announced the upcoming presentation of safety and tolerability data from its ProstACT Global Phase 3 study at the 2026 ASCO Annual Meeting. This trial evaluates TLX591-Tx, a prostate-specific membrane antigen (PSMA) targeted lutetium radio antibody-drug conjugate (rADC), in combination with standard of care (SoC) versus SoC alone for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). The study aims to reflect real-world clinical practices and facilitate broader geographic adoption of this innovative therapy.

The significance of the ProstACT Global study lies in its potential to reshape treatment paradigms for mCRPC. The safety and dosimetry lead-in phase has already demonstrated that TLX591-Tx, primarily cleared through the liver, exhibits minimal kidney toxicity, a common concern with existing PSMA-targeted therapies. Additionally, the large molecular weight of TLX591-Tx results in reduced uptake in salivary and lacrimal glands, potentially alleviating side effects such as dry mouth and dry eyes. These findings suggest that TLX591-Tx could provide a more tolerable treatment option for patients while maintaining therapeutic efficacy.

The takeaway from this development is its potential to accelerate the timeline for drug development in the field of prostate cancer. By demonstrating a favorable safety profile and addressing significant adverse effects associated with current therapies, TLX591-Tx may facilitate faster regulatory approval processes and enhance patient enrollment in subsequent trial phases. This shift could lead to more effective treatment options being available to clinicians and patients sooner, ultimately improving healthspan outcomes in the mCRPC population.

Source: globenewswire.com